FREEDOM! AHA lifts embargo on bypass vs. stent study after its vendor breaks it
From an email that went out at 7:46 p.m. Eastern tonight — just 12 minutes before the scheduled lift:
Media Alert! Embargo Lifted on Freedom Trial Results
LOS ANGELES, Nov. 4, 2012 (GLOBE NEWSWIRE) — As of 3:20 p.m. PT/6:20 p.m. ET on Sunday, Nov. 4, 2012, the American Heart Association has lifted the embargo on its news release on the “Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal management of Multivessel disease” (FREEDOM) trial, which had been embargoed until 4:58 p.m. PT/7:58 p.m. ET on Sunday, Nov. 4, 2012. The release was inadvertently sent out over the national wire by the association’s vendor GlobeNewswire.
The AHA would like to thank the news media who continue to abide by our embargo policy.
The study was published simultaneously in the New England Journal of Medicine.
This is at least the second time this year that the AHA has broken their own embargo. The first time was in July, on a statement about artificial sweeteners.
As I noted in July:
The AHA joins an august group of organizations who have broken their own embargoes: The journal Neurology (twice), the American Association for Cancer Research (AACR), and the Archives of Dermatology. As far as we know, none of them have faced sanctions, unlike reporters who break AHA embargoes.